Physician profile
Robert C Franklin
NPI 1164533329
$1,835.83
in general payments reported to CMS, 2019-2025
11 companies · $54.08 in 2025
The $54.08 reported for 2025 was less than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $40.70 · 2022: $148 · 2023: $617 · 2024: $623 · 2025: $54.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $765.76 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.70 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $170.91 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $168.74 | 2019-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $106.06 | 2019 | |
| Neurocrine Biosciences, INC. | $104.12 | 2023-2024 | Ingrezza |
| Indivior INC. | $81.36 | 2019-2023 | Perseris |
| Abbvie INC. | $55.78 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $44.15 | 2024 | Austedo Xr, Uzedy |
| Janssen Scientific Affairs, LLC | $35.62 | 2023 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $28.63 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.